Ipilimumab is a monoclonal antibody used in cancer immunotherapy. It functions as an immune checkpoint inhibitor by targeting CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, ipilimumab enhances the body's immune response against cancer cells.
